Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Ammatuna
Emanuele
E
Montefusco
Enrico
E
Pacilli
Matteo
M
Divona
Mariadomenica
M
Ardiri
Davide
D
Centonze
Diego
D
Lo-Coco
Francesco
F
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D010087:Oxides / Q000627:therapeutic use; D012074:Remission Induction; D059005:Topoisomerase II Inhibitors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001152:Arsenicals; D004791:Enzyme Inhibitors; D010087:Oxides; D059005:Topoisomerase II Inhibitors; D008942:Mitoxantrone; D000077237:Arsenic Trioxide